Fig. 3. Survival days for the groups of mice immunized with HSP70 derived from other syngeneic tumor cell lines. / Ten days after BMT, recipient mice were inoculated with 2.5 × 104 A20 cells (day 0). Mice were immunized with HSPs on day 4, 9, 14, and 19, immunized with PBS (○), 40 μg HSP70 derived from A20 cells (■), 40 μg HSP70 derived from T27A cells (▴), and 40 μg HSP70 derived from colon 26 cells (●). Mice immunized with HSP70 derived from A20, but not HSP70 derived from other syngeneic tumor cells, had significantly enhanced survival. *P < .05 versus PBS, T27A and, colon 26; Wilcoxon test. There were 5 mice in each group. Data are representative of 3 separate experiments.
Fig. 3.

Survival days for the groups of mice immunized with HSP70 derived from other syngeneic tumor cell lines.

Ten days after BMT, recipient mice were inoculated with 2.5 × 104 A20 cells (day 0). Mice were immunized with HSPs on day 4, 9, 14, and 19, immunized with PBS (○), 40 μg HSP70 derived from A20 cells (■), 40 μg HSP70 derived from T27A cells (▴), and 40 μg HSP70 derived from colon 26 cells (●). Mice immunized with HSP70 derived from A20, but not HSP70 derived from other syngeneic tumor cells, had significantly enhanced survival. *P < .05 versus PBS, T27A and, colon 26; Wilcoxon test. There were 5 mice in each group. Data are representative of 3 separate experiments.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal